<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155541</url>
  </required_header>
  <id_info>
    <org_study_id>A7471048</org_study_id>
    <nct_id>NCT04155541</nct_id>
  </id_info>
  <brief_title>Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)</brief_title>
  <official_title>Special Investigation for Vizimpro Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical
      practice
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">December 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number and proportion of patients with ILD (interstitial lung disease)</measure>
    <time_frame>52 weeks form the start date</time_frame>
    <description>The number and proportion of patients with ILD (interstitial lung disease) will be tabulated by subgroup by risk factor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>52 weeks from the start date</time_frame>
    <description>Response rate will be calculated. The response rate is defined as the propotion of patients with a best ovarall response of CR ro PR in the effectiveness analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and popuration of patients with adverse reactions</measure>
    <time_frame>52 weeks from the start date</time_frame>
    <description>The number and popuration of patients with adverse reactions will be tabulated.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">888</enrollment>
  <condition>EGFR Mutation-positive Inoperable or Reccrent NSCLC</condition>
  <arm_group>
    <arm_group_label>VIZIMPRO(dacomitinib hydrate)</arm_group_label>
    <description>Patients with EGFR mutation-positive inoperable or recorrent NSCLN (non-small cell lung cancer) who have not received VIZIMPRO (dacomitinib hydrate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacomitinib hydrate</intervention_name>
    <description>The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.</description>
    <arm_group_label>VIZIMPRO(dacomitinib hydrate)</arm_group_label>
    <other_name>VIZIMPRO</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient who meet the inclusion criteria and who were registered to this study within 28
        days including the start date of treatment with this product will be subjects for this
        study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with EGFR mutation-positive inoprable or recurrent NSCLC who have not received
             VIZIMPRO(dacomitinib hydrate)

        Exclusion Criteria:

          -  Exclusion criteria is not provided in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A7471048</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VIZIMPRO</keyword>
  <keyword>EGFR mutation-positive inoperable or recurrent NSCLC</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

